IQVIA Holdings Inc. (IQV)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I see IQVIA as a scaled healthcare-information and clinical-research business, with 94,000 employees and three segments serving life-sciences customers. Its data, software, and trial-workflow integration create switching costs, but I would not call the moat the widest. The filed record shows steady top-line progress: FY2023 revenue was $15.0B, FY2024 $15.4B, and FY2025 $16.3B, while diluted EPS went from $7.29 to $7.49 to $7.84. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $4.2B and net income $274.0M, versus revenue of $3.8B and net income of $249.0M in fiscal Q1 2025. FairStock classifies it as a STALWART — steady growth: profit 37.3% a year over 5 years, revenue 7.5%. Financial health is mixed: FairStock's ROE is 22.82%, but its ROCE is only 5.06%, debt/equity is 2.58, and Altman Z-score is 1.66. At the $273.60 close on 2026-10-26, FairStock's P/E is 33.99, P/B is 7.30, FCF yield is 4.8%, and EV/EBITDA is 17.28. The Graham Number of $82.40 implies a -239.03% margin of safety, so price is far above a conservative asset-and-earnings anchor. Piotroski 6/9 is decent, not exceptional. I like the cash generation—$2.2B trailing FCF—but the price already assumes better execution than the recent profit record proves.

In plain English: IQVIA helps drug companies run clinical trials and use healthcare data and software. The business is large and produces cash, but profit has been uneven and it carries a lot of debt. At the 2026-10-26 close, the shares look expensive compared with the company's recent profits and balance-sheet value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer